Vanderbilt Kennedy Center

Social Withdrawal in Fragile X: Can medication help adolescents and young adults?

Last Updated: Wednesday, January 16, 2013

Principal Investigator: Jeremy M. Veenstra-VanderWeele, M.D.

Other researchers: Cassandra Newsom, PhD and Kevin Sanders, MD

Learn more about Research Family Partners

Description

Vanderbilt University has studied a new medication to help with agression, irritability and moodiness in children and teens with Fragile X. Our results indicated improvement in social withdrawal. The purpose of this study is to find out if STX209 (R-Baclofen) is effective in treating social withdrawal in people with Fragile X. This randomized placebo-controlled study will help us determine whether the effects we saw before can be seen in a new group of people.

The study lasts 12 weeks. It involves 7 visits to Vanderbilt University in Nashville, TN. We need you to give blood at several of those visits.

There is no cost to you for being in this research study. You will get evaluations from a psychologist and psychiatrist during your study visits, and study medications at no cost.

Sponsored by Seaside Therapeutics.

Read more about Fragile X research at Vanderbilt by clicking here.

Participant Criteria

Adolescents and young adults (12-25 years old) with Fragile X syndrome

Compensation

$25 per visit in a check mailed to your home

Visit Requirements

7 visits to Vanderbilt University in Nashville, TN.

Brochure

Download Brochure

Contact Information

Sarah Marler
(615) 936-3288
sarah.marler@vanderbilt.edu

Want to Participate in this Study?

Enter your name and contact information and this study's coordinators will contact you if there are openings available.

 
 
(Optional)

Jeremy M. Veenstra-VanderWeele, M.D. needs participants for these other studies.

Visit this investigator's people page to list all of their studies together.